

Oncogenes, tumour suppressor genes and molecular markers in renal cell carcinoma

Poster Session 74

Monday, 27 March
14:00 - 15:30

Location: Room Berlin, North Hall (Level 1)

Chairs: A. Bex, Amsterdam (NL)
K. Junker, Homburg (DE)
M. Uemura, Toyonaka Osaka (JP)

Aims and objectives of this session

To discuss the molecular biology of renal tumors

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- 976 **PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness**
By: Qu Y-Y., Chang K., Dai B., Zhu Y., Zhang H-L., Ye D-W.
Institutes:Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China
- 977 **Risk assessment for ccRCC patients based on alterations in specific chromosomal regions**
By: Grimm J.¹, Janssen M.¹, Wagenpfeil S.², Hartmann A.³, Stöhr C.³, Kunath F.⁴, Stöckle M.¹, Junker K.¹
Institutes:¹Saarland University Medical Center, Dept. of Urology and Pediatric Urology, Homburg/Saar, Germany, ²Saarland University Medical Center, Institute of Medical Biometry, Epidemiology and Medical Informatics, Homburg/Saar, Germany, ³University Hospital Erlangen, Institute of Pathology, Homburg/Saar, Germany, ⁴University Hospital Erlangen, Dept. of Urology, Homburg/Saar, Germany
- 978 **Overexpression of miR-27a-3p is an independent prognostic factor for recurrence in clear cell renal cell carcinoma**
By: Uemura M., Nakata W., Kawashima A., Ujike T., Nagahara A., Fujita K., Nonomura N.
Institutes:Osaka University Graduate School of Medicine, Dept. of Urology, Suita, Osaka, Japan
- 979 **Validation and target identification of metastasis-associated miRNAs as prognostic markers in clear cell renal cell cancer**
By: Heinzelmann J.¹, Hoelters S.¹, Arndt M.¹, Pleyers R.¹, Fecher-Trost C.², Schalkowsky P.², Janssen M.¹, Pryalukhin A.³, Stöckle M.¹, Junker K.¹
Institutes:¹Saarland University, Dept. of Urology and Pediatric Urology, Homburg, Germany, ²University of The Saarland, Experimental and Clinical Pharmacology and Toxicology, Homburg, Germany, ³University Hospital of Saarland, Institute of Pathology, Homburg, Germany
- 980 **Long noncoding RNA BX357664 regulates cell proliferation and epithelial-to-mesenchymal transition via inhibiting TGF-beta 1/p38/HSP27 signaling in renal cell carcinoma**
By: Zengjun W., Liu Y., Qian J., Li X., Chen W., Xu A., Zhao K., Hua Y., Huang Z., Zhang J., Liang C., Su S., V P., Shao P., Li J., Qin C.
Institutes:The First Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China
- 982 **Functional variants in the low-density lipoprotein receptor gene are associated with clear cell renal cell carcinoma susceptibility**
By: Zhang G-M.¹, Wang M-Y.², Zhu Y.³, Gu C-Y.³, Wan F-N.³, Wei Q-Y.², Ye D-W.³
Institutes:¹The Affiliated Hospital of Qingdao University, Dept. of Urology, Qingdao, China, ²Fudan

University Shanghai Cancer Center, Cancer Institute, Shanghai, China, ³Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

- 983 **Tumor suppressor versus oncogenic role of the new N-hydrolase DNP1 in kidney and prostate cancers**
By: Danilin S.¹, Amiable C.², Coquard C.¹, Kaminski P-A.², Paoletti J.², Rothhut S.¹, Hamaidi I.³, Lindner V.⁴, Lang H.⁵, Pochet S.², Massfelder T.¹
Institutes:¹Inserm U1113, Team 3, Dept. of Cellular Signalisation and Communication In Kidney and Prostate Cancers, Strasbourg, France, ²Pasteur Institute, Biocatalyse and Chemistry Unit, Paris, France, ³Inserm U1113, Team 3, Cellular Signalisation and Communication In Kidney and Prostate Cancers, Strasbourg, France, ⁴Strasbourg University Hospital, Dept. of Pathology, Strasbourg, France, ⁵Strasbourg University Hospital, Dept. of Urology, Strasbourg, France
- 984 **Epigenetic inactivation of HOXA11 as a novel functional tumor suppressor for renal cell carcinoma**
By: Wang L., Cui Y., Sheng J.D., Yang Y., Kuang G.Y., Fan Y., Jin J., Zhang Q.
Institutes: Peking University First Hospital, Dept. of Urology, Beijing, China
- 985 **Systematic expression analysis of the mitochondrial complex III subunits identifies UQCRC1 as biomarker in clear cell renal cell carcinoma**
By: Ellinger J.¹, Gromes A.¹, Poss M.¹, Brüggemann M.¹, Schmdit D.¹, Ellinger N.², Tolkach Y.³, Dietrich D.³, Kristiansen G.³, Müller S.C.¹
Institutes:¹Universitätsklinikum Bonn, Dept. of Urology, Bonn, Germany, ²Universitätsklinikum Bonn, Dept. of Anesthesia and Intensive Care, Bonn, Germany, ³Universitätsklinikum Bonn, Dept. of Pathology, Bonn, Germany
- 986 **LOXL2 status correlates with tumor stage and regulates integrin levels to promote tumor progression in ccRCC**
By: Uemura M.¹, Hase H.², Kawashima A.¹, Ujike T.¹, Nagahara A.¹, Fujita K.¹, Tsujikawa K.², Nonomura N.¹
Institutes:¹Osaka University Graduate School of Medicine, Dept. of Urology, Suita, Osaka, Japan, ²Osaka University Graduate School of Pharmaceutical Sciences, Laboratory of Molecular and Cellular Physiology, Suita, Osaka, Japan
- 987 **Validation of BRCA1 associated protein-1 (BAP-1) as an adverse prognostic factor and investigations into the impact of BAP1 loss on the vascular endothelial growth factor (VEGF) pathway in clear cell renal cell carcinoma (ccRCC)**
By: Skibbe M.², Guenther K.², Kapur P.³, Huang J.⁴, Beldegrun A.⁵, Burchardt M.¹, Zimmermann U.¹, Gu Y-F.⁶, Wolff N.⁶, Brugarolas J.⁶, Lillig C.², Pantuck A.⁵, Kroeger N.¹
Institutes:¹Ernst-Moritz-Arndt University Greifswald, Klinik und Poliklinik für Urologie, Greifswald, Germany, ²Ernst-Moritz-Arndt University Greifswald, Institute of Medical Biochemistry and Molecular Medicine, Greifswald, Germany, ³University of Texas Southwestern Medical Center, Dept. of Pathology, Dallas, United States of America, ⁴David Geffen School of Medicine, University of California-Los Angeles, Dept. of Pathology and Laboratory Medicine, Los Angeles, United States of America, ⁵David Geffen School of Medicine At The University of California Los Angeles, The Institute of Urologic Oncology, Department of Urology, Los Angeles, United States of America, ⁶University of Texas Southwestern Medical Center, Dept. of Internal Medicine, Dallas, United States of America
- 988 **Targeting Lim1 oncogene has a therapeutic potential in advanced human renal cell carcinoma**
By: Hamaidi I.¹, Danilin S.², Dormoy V.³, Rothhut S.¹, Coquard C.¹, Barthelmebs M.¹, Béraud C.⁶, Lindner V.⁴, Lang H.⁵, Massfelder T.¹
Institutes:¹Inserm U1113 Team 3, Dept. of Urology, Strasbourg, France, ²FIRALIS, Dept. of Urology, Hunningue, France, ³Inserm UMRS 903, Dept. of Urology, Reims, France, ⁴HUS, Hôpital De Hautepierre, Dept. of Pathology, Strasbourg, France, ⁵HUS, Nouvel Hôpital Civil, Dept. of Urology, Strasbourg, France, ⁶Urolead, Dept. of Urology, Strasbourg, France
- 989 **Receptor activator of NF-κ B (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma**

By: Steven A.¹, Kroeger N.², Leisz S.¹, Fussek S.², Nowroozizadeh B.³, Huang J.³, Brandstetter D.⁴, Dougall B.⁴, Burchardt M.², Beldegrun A.⁵, Seliger B.⁶, Pantuck A.⁵

Institutes:¹Martin Luther University Halle/wittenberg, Medical Immunology At, Halle, Germany, ²Ernst-Moritz-Arndt University, Dept. of Urology, Greifswald, Germany, ³David Geffen School of Medicine At The University of California, Dept. of Pathology and Laboratory Medicine, Los Angeles, United States of America, ⁴Amgen Inc., Dept. of Hematology and Oncology Research, Seattle, United States of America, ⁵David Geffen School of Medicine At The University of California, Los Angeles, Institute of Urologic Oncology, Dept. of Urology, Los Angeles, United States of America, ⁶Martin Luther University Halle/wittenberg, Medical Immunology At, Halle, Unknown